Cancer and Metastasis Reviews

Papers
(The median citation count of Cancer and Metastasis Reviews is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer206
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities143
Regulation of dormancy during tumor dissemination: the role of the ECM104
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms86
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression77
Clonal tracking in cancer and metastasis74
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective71
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions66
The functions and modifications of tRNA-derived small RNAs in cancer biology65
Obesity and cancer53
The role of microbiome in pancreatic cancer49
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations48
Targeting lipid metabolism in cancer: neuroblastoma48
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor48
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer48
CAR T-cell therapy to treat multiple myeloma: current state and future directions47
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review47
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?47
Cell-cell interactions mediating primary and metastatic breast cancer dormancy44
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond43
p73 isoforms meet evolution of metastasis40
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients40
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?39
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives39
Preface37
Biography—Mathieu Boissan, Pharm.D., Ph.D36
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer35
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance34
Neuropeptide Y in cancer—biological functions and potential clinical implications33
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy31
Biographies31
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis30
The role of cancer cell bioenergetics in dormancy and drug resistance30
Biographies30
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications30
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance30
Targeting DNA damage repair pathways in pancreas cancer29
Short-chain fatty acids in cancer pathogenesis28
Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology28
Clusterin: a marker and mediator of chemoresistance in colorectal cancer27
Tumor necrosis factor superfamily signaling: life and death in cancer27
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development26
The emerging roles of histone demethylases in cancers24
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy24
Clinical interventions to break the obesity and cancer link: a narrative review24
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions24
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy23
Functional and clinical roles of stromal PDGF receptors in tumor biology23
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions23
Kenneth V. Honn, Ph.D. (1946–2023)23
Vaping and tumor metastasis: current insights and progress23
Impact of posttranslational modifications in pancreatic carcinogenesis and treatments23
Carcinoma of unknown primary (CUP): an update for histopathologists23
Debris-stimulated tumor growth: a Pandora’s box?22
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution22
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy22
HOXA9 transcription factor is a double-edged sword: from development to cancer progression21
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape21
OX40/OX40 ligand and its role in precision immune oncology21
Inflammatory bowel disease and carcinogenesis21
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review21
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective20
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies20
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect20
The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance20
New progress of tuberculosis scar carcinoma20
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases20
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting20
Biographies19
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs19
Ferroptosis: iron release mechanisms in the bioenergetic process19
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment19
Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX18
Is cancer an intelligent species?18
Metastasis suppressor genes in clinical practice: are they druggable?17
The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets17
Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets17
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases17
Oncobiology and treatment of breast cancer in young women17
Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancer17
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics17
Metastasis suppressor genes and their role in the tumor microenvironment17
The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers17
Lost at SCLC: a review of potential platinum sensitizers15
Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy15
De- “bug”-ing the microbiome in lung cancer15
The role of bone marrow adipocytes in cancer progression: the impact of obesity14
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer14
The cure from within? a review of the microbiome and diet in melanoma14
Glycosylation as a regulator of site-specific metastasis14
The diversity of natural killer cell functional and phenotypic states in cancer14
White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions13
Biography—Mikhail Kolonin13
Preface13
Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis13
Preface13
Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma13
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer13
Where is Waldo? or find the platelet13
Role of myeloid-derived suppressor cells in tumor recurrence13
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors12
The role of metabolic ecosystem in cancer progression — metabolic plasticity and mTOR hyperactivity in tumor tissues12
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics12
The role of the metabolite cargo of extracellular vesicles in tumor progression12
Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?12
Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance12
The role of obesity and bariatric surgery-induced weight loss in breast cancer12
Notch signaling in malignant gliomas: supporting tumor growth and the vascular environment12
Biographies12
Nanotechnology-aided advancement in the combating of cancer metastasis11
Minimally invasive biomarkers for triaging lung nodules—challenges and future perspectives11
Multiomics approach towards characterization of tumor cell plasticity and its significance in precision and personalized medicine11
Epigenetic drugs in cancer therapy11
Potential biomarkers for immunotherapy in non-small-cell lung cancer11
The roles of periostin derived from cancer-associated fibroblasts in tumor progression and treatment response10
Models of pancreatic ductal adenocarcinoma10
Insights into the role of senescence in tumor dormancy: mechanisms and applications10
Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies10
Epigenetic control of pancreatic cancer metastasis10
Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings10
The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin10
The timing of adiposity and changes in the life course on the risk of cancer10
Correction to: Connecting the human microbiome and pancreatic cancer10
Epigenetic markers and therapeutic targets for metastasis9
Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance9
Evolving strategies for addressing CAR T-cell toxicities9
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response9
Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance9
Preface9
Natural compounds targeting nuclear receptors for effective cancer therapy9
Oral delivery of RNAi for cancer therapy9
Advancements in gene therapies targeting mutant KRAS in cancers8
What do cellular responses to acidity tell us about cancer?8
Epigenetic changes and the dynamic heterogeneity of the metastatic phenotype – challenges ahead8
Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma8
Recapitulating the potential contribution of protein S-palmitoylation in cancer8
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance8
Neuronal mimicry in tumors: lessons from neuroscience to tackle cancer8
Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases8
Melanoma in people living with HIV: Immune landscape dynamics and the role of immuno- and antiviral therapies8
Glioblastoma stem cell metabolism and immunity8
Retraction Note: EET signaling in cancer8
0.035019874572754